Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.

From Your Site Articles

Eli Lilly is looking to Houston for a new facility. Getty Images

Pharmaceutical giant plans $5.9B Houston facility and more news to know

Trending News

Editor's note: It's time to look back at the top Houston innovation news from the second half of May 2025. From exciting VC raises to major manufacturing facilities in the works, here are the most-read InnovationMap stories from May 16-30.

1. Pharmaceutical giant looks to bring $5.9 billion facility to Houston

Eli Lilly is looking to build an active pharmaceutical ingredient manufacturing facility at Generation Park. Rendering courtesy of McCord

Pharmaceutical company Eli Lilly and Company is looking to build a $5.9 billion active pharmaceutical ingredient (API) manufacturing facility in Houston, according to a recent filing with the state of Texas.

The proposal states that the project plans to employ 604 full-time direct employees at the site upon ramp-up completion. Construction is projected to begin in 2026, with a completion target of 2030 and commercial operations beginning in 2031. Continue reading.

2. Houston VC firm closes $21M fund for underrepresented founders

Zach Ellis, founder and general partner of South Loop Ventures, which recently closed its debut fund. Photo via LinkedIn

Houston-based South Loop Ventures recently closed its debut fund for more than $21 million, led by investments from Rice Management Company and Chevron Technology Ventures.

The funds will go toward teams with at least one underrepresented founder of color working in the energy, health, space, sports and fintech sectors. Additional investments came from The Great Commission Foundation of the Episcopal Diocese of Texas, Texas CapitalBank and others organizations. Continue reading.

3. Houston-founded startup raises $1.2M and moves headquarters to Detroit

ChurchSpace, founded in Houston by Day Edwards and Emmanuel Brown, is moving to Detroit. Photo courtesy ChurchSpace.

Houston-founded ChurchSpace, known as the Airbnb for churches, has formed an official partnership with the City of Detroit and will relocate its headquarters.

The announcements come as the company successfully closed a $1.2 million oversubscribed funding round. The round was led by California-based Black Ops Ventures, with participation from Michigan Rise and Dug Song of Minor Capital, who is also the founder of the Song Foundation, another Michigan-based organization. Continue reading.

4. Houston aerospace co. soars with first U.S. test flight of hypersonic engine

Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind. Continue reading.

5. Houston regenerative medicine company expands lab for future trials

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. With its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research. Continue reading.

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

Houston regenerative medicine company expands lab for future trials

new digs

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. Fibroblasts are the primary variety of cells that compose connective tissue. FibroBiologics has found in studies that fibroblasts can be even more powerful than stem cells when it comes to both regeneration and immune modulation, meaning they could be a more versatile way forward in those fields.

In 2023, FibroBiologics moved into new lab space in the UH Technology Bridge. Now, with its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research.

The new space includes more than 10,000 square feet of space devoted to both labs and offices. The location is large enough to also house manufacturing drug product candidates that will be used in upcoming trials. Additionally, the company reports that it plans to hire additional researchers to help staff the facility.

“This expansion marks a transformative step forward for our company and our mission,” Pete O’Heeron, FibroBiologics founder and CEO, said in a news release. “By significantly increasing the size of our lab, we are creating the space and infrastructure needed to foster greater innovation and accelerate scientific breakthroughs.”

The streamlined, in-house manufacturing process will reduce the company’s reliance on external partners and make the supply chain simpler, O’Heeron added in the release.

Hamid Khoja, the chief scientific officer for FibroBiologics, also chimed in.

“To date, our progress in developing potentially transformative therapeutic candidates for chronic diseases using fibroblasts has been remarkable,” he added in the release. “This new laboratory facility will enable further expansion and acceleration of our research and development efforts. Additionally, the expansive new space will enable us to bring in-house currently outsourced projects, expand our science team and further contribute to the increased efficiency of our R&D efforts.”

This news arrives shortly after a milestone for the company in its research about neurodegenerative disease. Last month, fibroblast treatments in an animal model study demonstrated a notable regeneration of the myelin sheath, the layer that insulates nerves and is worn down by disease.

“Confirming remyelination in a second validated animal model is an important step in our research and development efforts, offering fresh hope for patients with demyelinating diseases, including multiple sclerosis,” O’Heeron added in a separate release. “These findings advance our mission to develop transformative fibroblast-based therapies that address the root causes of chronic disease, not just their symptoms, and reflect our dedication to pushing the frontiers of regenerative medicine."

The event spotlighted the organization’s strides in regenerative medicine, fueling advancements in adult stem cell therapies for conditions often deemed incurable, such as Parkinson’s Disease, multiple sclerosis, and spinal cord injuries. Photo via Si Vo

Houston gala attendees prescribe $1M for groundbreaking stem cell research

breaking boundaries

There’s a new gala in H-town, folks, and it made its grand, sold-out debut thanks to a power couple known for believing that the sky's the limit when it comes to local philanthropy. Chairs Jessica Rossman and Gordon Bethune piloted the inaugural Hope Biosciences Research Foundation (HBRF) fundraiser on October 26 at the Post Oak Hotel in Uptown Houston.

The evening offered patrons a deeper look into the group’s pioneering work, led by co-founders Donna and Daniel Chang. More than 400 supporters — many of whom have witnessed the impact of HBRF’s clinical trials on their health and the lives of loved ones — were enticed to partake in the event by a host committee helmed by Donae, Bella, and Rob Chramosta.

Sherry Diers and David Gonzales, hosts of the foundation’s Hopeful News Network podcast, shared heartfelt stories from their hands-on experiences with HBRF patients. In a touching moment, high school senior Bella Chramosta recounted her own health journey before announcing the inaugural HBRF Luminary Award recipients — Ema Suljkanovic, Rachel Phillips, and Alayna Nunez. The three Kingwood High School students had raised $1,400 for the foundation, and Houston icon Jim “Mattress Mack” McIngvale proudly presented the award.

HBRF offered a Hope-inspired jewelry pull, sponsored by Thomas Markle Jewelers. Each silver necklace entry doubled as a ticket for a chance to win a diamond version of the necklace — 2.27 carats in 18kt white gold, valued at $7,500. The winning ticket, drawn by Sarah and Phillip Markle, brought cheers from those who purchased necklaces throughout the evening. Guests enjoyed a silent auction chaired by Cathy Jackson, featuring everything from health and beauty experiences to travel packages like golfing at St. Andrews and fishing in Cabo.

Gala-goers were treated to a meaningful musical performance by Faith and Jon Hartlage. Upon departure, each guest received a gift from Hope Biosciences, LLC — a tube of Wondercell gel, an anti-aging product made from stem cell byproducts, as a reminder of the foundation’s impact both inside and outside the lab.

Seen on the scene were Ginger and Dick Hite, Maria and Omar Alaoui, Roslyn Bazzelle Mitchell, Cheryl Byington, Gracie and Bob Cavnar, Anna Dean, Karen and Peter Remington, Dr. Romy Dell’Ario, Jan Duncan, Nene Foxhall, Mandy Kao, Stacey Lindseth, Linda McIngvale, Beth Muecke, Patti Murphy, Jennifer Pinkerton, Rachel and Tom Regan, Dallas Rowdan, Ally Shell, Natalie Wall, Christina Zhou, Tama Lundquist and Dr. Peter Farrell, Stephanie and Gary Loveless, Azeemeh Zaheer, Chris Perry, Gregg Harrison, and Dr. Roland Maldonado.

------

This article originally ran on CultureMap.

FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas cybersecurity co. expands unique train-to-hire model to Houston

job search

It’s increasingly more difficult to ensure the confidentiality, integrity, and availability of proprietary data and information in the ever-changing, ever-evolving digital world.

Cyberattacks, including malware, phishing, and ransomware, are becoming increasingly common and sophisticated, posing a consistent threat to a company’s sustainability and bottom line.

To combat that trend, Nukudo, a San Antonio-based cybersecurity workforce development company, is expanding its initiative to bridge the global cybersecurity talent gap through immersive training and job placement to Houston.

“We saw that there was a need in the market because there's a shortage of skilled manpower within the cybersecurity industry and other digital domains,” says Dean Gefen, CEO of NukuDo. “So, our initial goal was to take a large pool of people and then make them to be fully operational in cybersecurity in the shortest amount of time.”

The company refers to the plan as the “training-to-employment model,” which focuses on providing structured training to select individuals who then acquire the skills and knowledge necessary to secure and maintain fruitful careers.

The company identifies potential associates through its proprietary aptitude test, which recognizes individuals who possess the innate technical acumen and potential for success in various cybersecurity roles, regardless of their level of education.

“We take in people from all walks of life, meaning the program is purely based on the associate’s potential,” Gefen says. “We have people who were previously aircraft engineers, teachers, graphic designers, lawyers, insurance agents and so forth.”

Once selected, associates are trained by cybersecurity experts while gaining hands-on experience through scenario-based learning, enabling them to be deployed immediately as fully operational cybersecurity professionals.

The program training lasts just six months—all paid—followed by three years of guaranteed employment with NukuDo.

While in training, associates are paid $ 4,000 per month; then, they’re compensated by nearly double that amount over the next three years, ultimately pushing their salaries to well into the six figures after completing the entire commitment.

In addition to fostering a diverse talent pipeline in the cybersecurity field, NukuDo is creating a comprehensive solution to address the growing shortage of technical talent in the global workforce.

And arming people with new marketable skills has a litany of benefits, both professional and personal, Gefen says.

“Sometimes, we have associates who go on to make five times their previous salary,” says Gefen. “Add to that fact that we had someone that had a very difficult life beforehand and we were able to put him on a different path. That really hits home for us that we are making a difference.

Nulkudo currently has partnerships with companies such as Accenture Singapore and Singapore Airlines. Gefen says he and his team plans to have a new class of associates begin training every month by next year and take the model to the Texas Triangle (Houston, Austin and Dallas)—then possibly nationwide.

“The great thing about our program is that we train people above the level of possible threat of replacement by artificial intelligence,” Gefen says. “But what we are also doing, and this is due to requirements that we have received from clients that are already hiring our cyber professionals, is that we are now starting to deliver AI engineers and data scientists in other domains.”

“That means that we have added more programs to our cybersecurity program. So, we're also training people in data science and machine learning,” he continues.

All interested candidates for the program should be aware that a college degree is not required. NukuDo is genuinely interested in talented individuals, regardless of their background.

“The minimum that we are asking for is high school graduates,” Gefen says. “They don't need to have a college degree; they just need to have aptitude. And, of course, they need to be hungry to make this change.”

2 Houston universities declared among world’s best in 2026 rankings

Declaring the Best

Two Houston universities are in a class of their own, earning top spots on a new global ranking of the world's best universities.

Rice University and University of Houston are among the top 1,200 schools included in the QS World University Rankings 2026. Ten more schools across Texas make the list.

QS (Quacquarelli Symonds), a London-based provider of higher education data and analytics, compiles the prestigious list each year; the 2026 edition includes more than 1,500 universities from around the world. Factors used to rank the schools include academic reputation; employer reputation; faculty-student ratio; faculty research; and international research, students, and faculty.

In Texas, University of Texas at Austin lands at No. 1 in the state, No. 20 in the U.S., and No. 68 globally.

Houston's Rice University is close behind as Texas' No. 2 school. It ranks 29th in the U.S. and No. 119 in the world. Unlike UT, which fell two spots globally this year (from No. 66 to 68), Rice climbed up the charts, moving from 141st last year to No. 119.

University of Houston impresses as Texas' 4th highest-ranked school. It lands at No. 80 in the U.S. and No. 556 globally, also climbing about 100 spots up the chart.

Rice and UH are on a roll in regional, national, and international rankings this year.

Rice earned top-15 national rankings by both Niche.com and Forbes last fall. Rice claimed No. 1 and UH ranked No. 8 in Texas in U.S. News & World Report's 2025 rankings. Rice also topped WalletHub's 2025 list of the best colleges and universities in Texas for 2025.

More recently, in April, both UH and Rice made U.S. News' 2025 list of top grad schools.

In all, 192 U.S. universities made the 2026 QS World University Rankings — the most of any country. Topping the global list is the Massachusetts Institute of Technology (MIT).

“The results show that while U.S. higher education remains the global leader, its dominance is increasingly challenged by fast-rising emerging systems,” says the QS World University Rankings report. “A decade ago, 32 American universities [were] featured in the world’s top 100; today, that number has dropped to 26, and only 11 of these institutions have improved their position this year."

The 12 Texas universities that appear in the QS World University Rankings 2026 list are:

University of Texas at Austin, No. 20 in the U.S. and No. 68 in the world (down from No. 66 last year).
Rice University, No. 29 in the U.S. and No. 119 in the world (up from No. 141 last year).
Texas A&M University, No. 32 in the U.S. and No. 144 in the world (up from No. 154 last year).
University of Houston, No. 80 in the U.S. and No. 556 in the world (up from 651-660 last year).
University of Texas at Dallas, No. 85 in the U.S. and No. 597 in the world (down from 596 last year).
Texas Tech University, No. 104 in the U.S. and No. 731-740 in the world (unchanged from last year).
University of North Texas, No. 123 in the U.S. and No. 901-950 in the world (up from 1,001-1,200 last year)
Baylor University, tied for No. 136 in the U.S. and at No. 1,001-1,200 in the world (unchanged from last year).
Southern Methodist University, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
University of Texas Arlington, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
University of Texas at San Antonio, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
University of Texas at El Paso, No. 172 in the U.S. and at 1,201-1,400 in the world (down from 1,001-1,200 last year).

---

This article originally appeared on CultureMap.com.

Houston students develop new device to prepare astronauts for outer space

space race

Rice University students from the George R. Brown School of Engineering and Computing designed a space exercise harness that is comfortable, responsive, and adaptable and has the potential to assist with complex and demanding spacewalks.

A group of students—Emily Yao, Nikhil Ashri, Jose Noriega, Ben Bridges and graduate student Jack Kalicak—mentored by assistant professor of mechanical engineering Vanessa Sanchez, modernized harnesses that astronauts use to perform rigorous exercises. The harnesses are particularly important in preparing astronauts for a reduced-gravity space environment, where human muscles and bones atrophy faster than they do on Earth. However, traditional versions of the harnesses had many limitations that included chafing and bruising.

The new harnesses include sensors for astronauts to customize their workouts by using real-time data and feedback. An additional two sensors measure astronauts’ comfort and exercise performance based on temperature and humidity changes during exercise and load distribution at common pressure points.

“Our student-led team addressed this issue by adding pneumatic padding that offers a customized fit, distributes pressure over a large surface area to reduce discomfort or injuries and also seamlessly adapts to load shifts — all of which together improved astronauts’ performance,” Sanchez said in a news release. “It was very fulfilling to watch these young engineers work together to find innovative and tangible solutions to real-world problems … This innovative adjustable exercise harness transforms how astronauts exercise in space and will significantly improve their health and safety during spaceflights.”

The project was developed in response to a challenge posted by the HumanWorks Lab and Life Science Labs at NASA and NASA Johnson Space Center for the 2025 Technology Collaboration Center’s (TCC) Wearables Workshop and University Challenge, where teams worked to solve problems for industry leaders.

Rice’s adaptive harness won the Best Challenge Response Award. It was funded by the National Science Foundation and Rice’s Office of Undergraduate Research and Inquiry.

“This challenge gave us the freedom to innovate and explore possibilities beyond the current harness technology,” Yao added in the release. “I’m especially proud of how our team worked together to build a working prototype that not only has real-world impact but also provides a foundation that NASA and space companies can build and iterate upon.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME